3.98MMarket Cap-556P/E (TTM)
5.8000High4.9800Low103.45KVolume5.1800Open5.0400Pre Close563.71KTurnover15.33%Turnover RatioLossP/E (Static)712.68KShares34.220052wk High2.67P/B3.77MFloat Cap4.600052wk Low--Dividend TTM674.87KShs Float4647888000.0000Historical High--Div YieldTTM16.27%Amplitude4.6000Historical Low5.4490Avg Price1Lot Size
ReShape Lifesciences Stock Forum
ReShape Lifesciences (RSLS) reported Q3 2024 financial results, showing revenue growth of 16.6% over Q2 2024 and 6.4% year-over-year to $2.3 million.
The company achieved a 40.6% reduction in operating expenses for the first nine months of 2024 compared to 2023.
Gross profit margin improved to 62.8% in Q3 2024.
The company entered into a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys for $5.16 million.
ReSha...
ReShape Lifesciences: Entered Into Merger Agreement With Vyome Therapeutics & Asset Purchase Agreement With Biorad Medisys
4 mins ago
ReShape Lifesciences® Receives Health Canada Approval for Its Next-Generation Lap-Band® 2.0 Flex
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
ReShape Lifesciences (Nasdaq: RSLS) has received Health Canada approval for its next-generation Lap-Band® 2.0 FLEX and Tubing Kit. The enhanced device features new Flex technology that acts as a relief valve, allowing larger food pieces to pass through more easily by temporarily relaxing before returning to its resting diameter. Like its predecessor, the device can...
pumped to 11 dayumm
No comment yet